Portal de Periódicos da CAPES

P-120 NATIONAL SURVEY ON CURRENT PRACTICES TO PREVENT HBV REACTIVATION DURING IMMUNOSUPPRESSION

2021; Elsevier BV; Volume: 24; Linguagem: Inglês

10.1016/j.aohep.2021.100480

2659-5982

João Marcello de Araujo-Neto, M. Iasi, Letícia Cancella Nabuco, Fabrício Silva Pessoa, Eduardo Machado Vilela, R.S.B. Stucchi, Lígia Yukie Sassaki, Ana Karla Guedes de Melo, Ângela Jesus, Jéssica Fernandes Ramos, Maria Ignez Braghiroli, G. Pilleggi, D.M. Langhi-Junior, Anita Coutinho, Maria Lúcia Gomes Ferraz, Paulo Lisboa Bitencourt, Carlos Eduardo Brandão,

HIV/AIDS oral health manifestations

Reactivation of hepatitis B virus (HBVr) is a problem still neglected worldwide. To assess knowledge of physicians regarding HBVr during immunosuppression including use of immunobiologics (IS/IB). Between August and October 2020, a national survey regarding current practices in HBVr prevention was sent to members of the Brazilian Societies of Hepatology, Gastroenterology, Hematology, Rheumatology, Oncology and Transplantation using a web-based approach. 510 physicians answered the survey, mainly gastroenterologists (35%) and rheumatologists (31%). The majority had less than 20 years of clinical practice (62%). 91% reported to routinely request serology for HBV before IS/IB. To 90% of the interviewed doctors, in their clinical practice, serology is missing in less than 25% of their patients already using IS/IB. The most common serology panel requested (75%) is HBsAg, Anti-HBc and Anti-HBs. 76% recommend strategies to prevent HBVr for either HBsAg and/or anti-HBc-positive patients, however, 16% only prescribe to HBsAg-positive. 85% have an specialist on HBVr available for referring patients, but 30% start prevention strategies without the need for specialized evaluation. In this case, the preferred treatment options are entecavir (18%), tenofovir (17%) and lamivudine (6%). 88% reported good adherence of their patients to HBVr prevention strategy. Only 27% referred to maintain prevention strategy for at least 6 months after IS/IB interruption. Finally, 73% of the participants never experienced HBVr on their practice and 42% participated in educational activities about HBVr in the last 2 years. Compared to previous literature, Brazilian physicians seems to have a better compliance to international guidelines toward HBVr prevention. With the exception of duration of HBVr prophylaxis, medical knowledge on this field can be regarded as above average.